Cat. No.: HY-12163

Entinostat

(Synonyms: MS-275; SNDX-275)

91 Cited Publications

Customer Review

Based on 91 publication(s) in Google Scholar

Entinostat is an oral and selective class I HDAC inhibitor, with IC₅₀s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.

For research use only. We do not sell to patients.

Purity: 99.98%
CAS No.: 209783-80-2
Formula: C₂₁H₂₀N₄O₃
Molecular Weight:376.41

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 1 year , -20°C, 6 months

Entinostat Chemical Structure

CAS No.: 209783-80-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (91)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Entinostat is an oral and selective class I HDAC inhibitor, with IC₅₀s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.

IC₅₀ & Target^[1]

HDAC1

243 nM (IC₅₀)

HDAC3

248 nM (IC₅₀)

HDAC2

453 nM (IC₅₀)

All HDAC Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	3 μM Compound: 4, MS-275	Antiproliferative activity against human A2780 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human A2780 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
A2780	CC₅₀	3 μM Compound: 3, MS-275, SNDX-275	Antiproliferative activity against human A2780 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human A2780 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
A2780	IC₅₀	5.89 μM Compound: Entinostat	Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay	[PMID: 28340413]
A-375	IC₅₀	3.67 μM Compound: MS275	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
A-375	IC₅₀	3.67 μM Compound: MS275	Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A549	IC₅₀	8 μM Compound: 4 (MS-275)	Inhibitory concentration against lung A549 cell line Inhibitory concentration against lung A549 cell line	[PMID: 12593661]
A549	IC₅₀	3.58 μM Compound: MS-275 (4)	Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay	[PMID: 14667227]
A549	IC₅₀	3.58 μM Compound: 1g, MS-275	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 18247554]
A549	IC₅₀	1200 nM Compound: 4, MS-275	Antiproliferative activity against human A549 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human A549 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
A549	CC₅₀	1200 nM Compound: 3, MS-275, SNDX-275	Antiproliferative activity against human P53 expressing A549 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53 expressing A549 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
A549	IC₅₀	<0.1 μM Compound: MS-275	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22705022]
A549	IC₅₀	5.41 μM Compound: MS-275	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
A549	IC₅₀	5.41 μM Compound: Entinostat	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
A549	IC₅₀	3.134 μM Compound: MS-275	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26140961]
A549	IC₅₀	3.11 μM Compound: Entinostat	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28340413]
A549	GI₅₀	5.76 μM Compound: 6; MS-275	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
A549	GI₅₀	18.37 μM Compound: MS-275	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28629630]
A549	IC₅₀	1200 nM Compound: 6; MS-275	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	[PMID: 30476825]
A549	IC₅₀	7.15 μM Compound: MS275	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A549	IC₅₀	1.48 μM Compound: 5; MS-275	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
A549	IC₅₀	1.71 μM Compound: 2; MS-275	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based CCK-8 assay	[PMID: 34097389]
A549	IC₅₀	1.48 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
A549	IC₅₀	2.25 μM Compound: MS-275	Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
A549	IC₅₀	4.9 μM Compound: MS-275	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
ACHN	IC₅₀	2.4 μM Compound: MS-275	Antiproliferative activity against human ACHN cells after 72 hrs by MTT assay Antiproliferative activity against human ACHN cells after 72 hrs by MTT assay	[PMID: 29787262]
AGS	IC₅₀	0.34 μM Compound: MS-275	Antiproliferative activity against human AGS cells after 72 hrs by MTT assay Antiproliferative activity against human AGS cells after 72 hrs by MTT assay	[PMID: 29787262]
AGS	IC₅₀	26.67 μM Compound: MS-275	Cytotoxicity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
ASPC1	GI₅₀	6.9 μM Compound: 6; MS-275	Growth inhibition of human AsPC1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human AsPC1 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
B16-F10	IC₅₀	1.15 μM Compound: 2; MS-275	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell viability measured for 48 hrs in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone by microplate reader based MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell viability measured for 48 hrs in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone by microplate reader based MTT assay	[PMID: 34097389]
B16-F10	IC₅₀	2.26 μM Compound: 2; MS-275	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based MTT assay	[PMID: 34097389]
B16-F10	IC₅₀	9.27 μM Compound: MS-275	Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 39031090]
BGC-823	IC₅₀	26.98 μM Compound: MS-275	Cytotoxicity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
C6	IC₅₀	0.33 μM Compound: MS-275	Antiproliferative activity against rat C6 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against rat C6 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34656900]
DLD-1	IC₅₀	1.74 μM Compound: 5; MS-275	Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
DU-145	IC₅₀	1 μM Compound: 4 (MS-275)	Inhibitory concentration against prostate DU145 cell line Inhibitory concentration against prostate DU145 cell line	[PMID: 12593661]
DU-145	IC₅₀	2 μM Compound: MS-275	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 19131248]
DU-145	IC₅₀	3.75 μM Compound: MS-275; 84	Cytotoxicity against human DU-145 cells Cytotoxicity against human DU-145 cells	[PMID: 33077264]
Epithelial cell	IC₅₀	>20000 nM Compound: 4, MS-275	Antiproliferative activity against human renal epithelial cells by CellTiter-Blue cell viability assay Antiproliferative activity against human renal epithelial cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
Fibroblast	IC₅₀	20 μM Compound: MS-275	Toxicity in breast fibroblasts Toxicity in breast fibroblasts	[PMID: 18212103]
Fibroblast MRHF cell line	IC₅₀	>37 μM Compound: 4 (MS-275)	Inhibitory concentration against normal fibroblast MRHF cell line Inhibitory concentration against normal fibroblast MRHF cell line	[PMID: 12593661]
G-401	IC₅₀	1300 nM Compound: 4, MS-275	Antiproliferative activity against human G401 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human G401 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
G-401	CC₅₀	1300 nM Compound: 3, MS-275, SNDX-275	Antiproliferative activity against human G401 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human G401 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
GES1	IC₅₀	60.17 μM Compound: MS-275	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
HCT-116	IC₅₀	5.4 μM Compound: MS-275	Tested for antiproliferative activity against HCT116 colorectal human carcinoma cell using WST-1 assay Tested for antiproliferative activity against HCT116 colorectal human carcinoma cell using WST-1 assay	[PMID: 11992774]
HCT-116	IC₅₀	0.6 μM Compound: 4 (MS-275)	Inhibitory concentration against colon HCT116 cell line Inhibitory concentration against colon HCT116 cell line	[PMID: 12593661]
HCT-116	IC₅₀	0.5 μM Compound: MS-275	In vitro antiproliferative activity against human cancer cell line HCT116 using MTT assay In vitro antiproliferative activity against human cancer cell line HCT116 using MTT assay	[PMID: 14684344]
HCT-116	IC₅₀	0.5 μM Compound: 1g, MS-275	Inhibition of human HCT116 cells Inhibition of human HCT116 cells	[PMID: 18247554]
HCT-116	IC₅₀	700 nM Compound: 4, MS-275	Antiproliferative activity against human HCT116 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human HCT116 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
HCT-116	IC₅₀	27.47 μM Compound: MS-275	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 18701301]
HCT-116	CC₅₀	700 nM Compound: 3, MS-275, SNDX-275	Antiproliferative activity against human P53 expressing HCT116 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53 expressing HCT116 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
HCT-116	IC₅₀	0.8 μM Compound: MS-275	Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay	[PMID: 20452226]
HCT-116	IC₅₀	670 nM Compound: 6, SNDX-275	Antiproliferative activity against human HCT116 cells assessed as growth inhibition Antiproliferative activity against human HCT116 cells assessed as growth inhibition	[PMID: 21650221]
HCT-116	IC₅₀	0.67 μM Compound: 3, SNDX-275	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 21742496]
HCT-116	IC₅₀	0.76 μM Compound: MS-275	Antiproliferative activity against human HCT116 cells after 3 days by WST-1 assay Antiproliferative activity against human HCT116 cells after 3 days by WST-1 assay	[PMID: 22321215]
HCT-116	GI₅₀	0.6 μM Compound: MS-275, SNDX-275	Growth inhibition of human HCT116 cells after 2 days by MTT assay Growth inhibition of human HCT116 cells after 2 days by MTT assay	[PMID: 22541394]
HCT-116	IC₅₀	<0.1 μM Compound: MS-275	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22705022]
HCT-116	IC₅₀	0.78 μM Compound: MS-275	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
HCT-116	IC₅₀	5.1 μM Compound: MS-275	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26140961]
HCT-116	IC₅₀	2.03 μM Compound: Entinostat	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28340413]
HCT-116	IC₅₀	2.07 μM Compound: MS275	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28415009]
HCT-116	IC₅₀	0.47 μM Compound: MS275	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HCT-116	IC₅₀	0.47 μM Compound: MS275	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HCT-116	IC₅₀	0.82 μM Compound: 5; MS-275	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HCT-116	IC₅₀	1.72 μM Compound: 2; MS-275	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based MTT assay	[PMID: 34097389]
HCT-116	IC₅₀	2.48 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
HCT-116	IC₅₀	1.06 μM Compound: MS-275	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
HCT-116	IC₅₀	2.3 μM Compound: MS-275	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 39031090]
HCT-116	IC₅₀	0.56 μM Compound: MS-275	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
HEK293	IC₅₀	120 nM Compound: MS-275	Inhibition of HDAC1 in HEK293 cells Inhibition of HDAC1 in HEK293 cells	[PMID: 18308563]
HEK293	IC₅₀	400 nM Compound: MS-275	Inhibition of HDAC3 in HEK293 cells Inhibition of HDAC3 in HEK293 cells	[PMID: 18308563]
HEK293	IC₅₀	120 nM Compound: 3, MS-275, SNDX-275	Inhibition of human C-terminal FLAG-tagged HDAC1 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC1 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	250 nM Compound: 3, MS-275, SNDX-275	Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	400 nM Compound: 3, MS-275, SNDX-275	Inhibition of human C-terminal FLAG-tagged HDAC3 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC3 in HEK293 cells	[PMID: 19441846]
HEL	IC₅₀	1.29 μM Compound: MS275	Antiproliferative activity against HEL cells after 48 hrs by MTT assay Antiproliferative activity against HEL cells after 48 hrs by MTT assay	[PMID: 28415009]
HEL	IC₅₀	0.48 μM Compound: MS-275	Antiproliferative activity against HEL cells after 48 hrs by MTT assay Antiproliferative activity against HEL cells after 48 hrs by MTT assay	[PMID: 28511906]
HEL	IC₅₀	0.44 μM Compound: MS-275	Antiproliferative activity against human HEL cells after 72 hrs by MTT assay Antiproliferative activity against human HEL cells after 72 hrs by MTT assay	[PMID: 29787262]
HeLa	IC₅₀	1800 nM Compound: MS-275	Inhibition of HeLa cell proliferation Inhibition of HeLa cell proliferation	[PMID: 16987657]
HeLa	IC₅₀	1800 nM Compound: 4, MS-275	Antiproliferative activity against human HeLa cells by CellTiter-Blue cell viability assay Antiproliferative activity against human HeLa cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
HeLa	CC₅₀	1800 nM Compound: 3, MS-275, SNDX-275	Antiproliferative activity against human P53-deficient HeLa cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53-deficient HeLa cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
HeLa	IC₅₀	4.8 μM Compound: 80, MS-27580	Inhibition of HDAC from human HeLa cells assessed as of histone H3 acetylation Inhibition of HDAC from human HeLa cells assessed as of histone H3 acetylation	[PMID: 19534534]
HeLa	IC₅₀	3.2 μM Compound: MS-275	Inhibition of human HDAC in HeLa cells after 30 mins by Fluor de Lys fluorescence assay Inhibition of human HDAC in HeLa cells after 30 mins by Fluor de Lys fluorescence assay	[PMID: 21889343]
HeLa	IC₅₀	<0.1 μM Compound: MS-275	Inhibition of HDAC1 in human HeLa cell lysate using KI-104 as substrate after 40 mins by fluorescence analysis Inhibition of HDAC1 in human HeLa cell lysate using KI-104 as substrate after 40 mins by fluorescence analysis	[PMID: 22705022]
HeLa	IC₅₀	<0.1 μM Compound: MS-275	Inhibition of HDAC2 in human HeLa cell lysate using KI-104 as substrate after 40 mins by fluorescence analysis Inhibition of HDAC2 in human HeLa cell lysate using KI-104 as substrate after 40 mins by fluorescence analysis	[PMID: 22705022]
HeLa	IC₅₀	3160 nM Compound: MS-275	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay	[PMID: 23089527]
HeLa	IC₅₀	11.18 μM Compound: MS275	Inhibition of HDAC in human HeLa cells using Boc-Lys(AC)-AMC as substrate after 24 to 48 hrs by spectrofluorometry Inhibition of HDAC in human HeLa cells using Boc-Lys(AC)-AMC as substrate after 24 to 48 hrs by spectrofluorometry	[PMID: 26996372]
HeLa	IC₅₀	8.02 μM Compound: MS-275	Inhibition of HDAC in human HeLa cells using fluor de Lys as substrate incubated for 20 mins by microplate spectrofluorometric analysis Inhibition of HDAC in human HeLa cells using fluor de Lys as substrate incubated for 20 mins by microplate spectrofluorometric analysis	[PMID: 27060764]
HeLa	IC₅₀	>1000 nM Compound: 6; MS-275	Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Lys(Ac)-pNA as substrate after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Lys(Ac)-pNA as substrate after 30 mins by fluorescence assay	[PMID: 28395150]
HeLa	GI₅₀	19.24 μM Compound: MS-275	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28629630]
HeLa	IC₅₀	1.6 μM Compound: MS275	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HeLa	IC₅₀	>5 μM Compound: MS-275	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29787262]
HeLa	IC₅₀	1.33 μM Compound: MS275	Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 31003060]
HeLa	IC₅₀	2.36 μM Compound: MS275	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HeLa	IC₅₀	1190 nM Compound: MS-275	Inhibition of HDAC1/2 in human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay Inhibition of HDAC1/2 in human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay	[PMID: 32267687]
HeLa	IC₅₀	>4 μM Compound: 5; MS-275	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HepG2	IC₅₀	0.9 nM Compound: 1g, MS-275	Inhibition of human HepG2 cells Inhibition of human HepG2 cells	[PMID: 18247554]
HepG2	IC₅₀	60.12 μM Compound: MS-275	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 18701301]
HepG2	IC₅₀	4.54 μM Compound: 5; MS-275	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32325365]
HepG2	IC₅₀	1.76 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
HepG2	IC₅₀	1.57 μM Compound: MS-275	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 39031090]
HGC-27	IC₅₀	18.47 μM Compound: MS-275	Cytotoxicity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
HH	IC₅₀	0.49 μM Compound: 5; MS-275	Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HL-60	IC₅₀	4.53 μM Compound: Entinostat	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 28340413]
HL-60	IC₅₀	1.52 μM Compound: MS275	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 28415009]
HL-60	IC₅₀	0.37 μM Compound: 5; MS-275	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HL-60	GI₅₀	0.214 μM Compound: Entinostat	Antiproliferative activity against human HL-60 cells incubated for 3 days by alamar blue assay Antiproliferative activity against human HL-60 cells incubated for 3 days by alamar blue assay	[PMID: 38340642]
HMEC	IC₅₀	>37 μM Compound: 4 (MS-275)	Inhibitory concentration against normal epithelial HMEC cell line Inhibitory concentration against normal epithelial HMEC cell line	[PMID: 12593661]
Hs-578T	IC₅₀	1 μM Compound: 69	Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 24 hrs by ALDEFLUOR assay Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 24 hrs by ALDEFLUOR assay	[PMID: 33650861]
HT-1080	IC₅₀	>5 μM Compound: MS-275	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 29787262]
HT-29	IC₅₀	3.1 μM Compound: MS-275	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 29787262]
Huh-7	CC₅₀	5.1 μM Compound: 9, MS-275, SNDX-275	Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay	[PMID: 25490700]
Huh-7	EC₅₀	1.4 μM Compound: 9, MS-275, SNDX-275	Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay	[PMID: 25490700]
HuT78	IC₅₀	>1 μM Compound: 5; MS-275	Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HUVEC	IC₅₀	10 μM Compound: MS-275	Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	6 μM Compound: MS-275	Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	>100 μM Compound: Entinostat	Cytotoxicity against HUVEC after 48 hrs by MTT assay Cytotoxicity against HUVEC after 48 hrs by MTT assay	[PMID: 28340413]
Jurkat	IC₅₀	0.69 μM Compound: 2; MS-275	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based CCK-8 assay	[PMID: 34097389]
Jurkat	IC₅₀	0.25 μM Compound: MS-275	Antiproliferative activity against human Jurkat T cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay Antiproliferative activity against human Jurkat T cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay	[PMID: 39031090]
Jurkat	IC₅₀	0.28 μM Compound: MS-275	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
K562	IC₅₀	4.8 μM Compound: 1	Inhibitory activity against partially purified histone deacetylase of human leukemia K562 cells. Inhibitory activity against partially purified histone deacetylase of human leukemia K562 cells.	[PMID: 10425110]
K562	IC₅₀	2 μM Compound: MS 27-275	Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) prepared from K562 erythroleukemia cells. Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) prepared from K562 erythroleukemia cells.	[PMID: 12419380]
K562	IC₅₀	>30 μM Compound: MS-275	Inhibition of KDAC6 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method Inhibition of KDAC6 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	[PMID: 26681404]
K562	IC₅₀	>30 μM Compound: MS-275	Inhibition of KDAC8 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method Inhibition of KDAC8 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	[PMID: 26681404]
K562	IC₅₀	0.79 μM Compound: MS-275	Inhibition of KDAC3 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method Inhibition of KDAC3 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	[PMID: 26681404]
K562	IC₅₀	1.48 μM Compound: MS-275	Inhibition of KDAC1 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method Inhibition of KDAC1 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	[PMID: 26681404]
K562	IC₅₀	1.68 μM Compound: MS275	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28415009]
K562	IC₅₀	1.32 μM Compound: MS-275	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28511906]
K562	GI₅₀	9.32 μM Compound: MS-275	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28629630]
K562	IC₅₀	3.66 μM Compound: MS-275	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29787262]
K562	IC₅₀	21.3 μM Compound: MS-275; 84	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 33077264]
K562	IC₅₀	1.19 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
K562	IC₅₀	0.57 μM Compound: MS-275	Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
KB	IC₅₀	520 nM Compound: 6; MS-275	Growth inhibition of human KB cells after 48 hrs by SRB assay Growth inhibition of human KB cells after 48 hrs by SRB assay	[PMID: 30476825]
KB	GI₅₀	6.632 μM Compound: 8; MS-275	Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay	[PMID: 32171161]
KG-1	IC₅₀	>5 μM Compound: MS-275	Antiproliferative activity against human KG1 cells after 72 hrs by MTT assay Antiproliferative activity against human KG1 cells after 72 hrs by MTT assay	[PMID: 29787262]
KG-1	IC₅₀	0.42 μM Compound: 5; MS-275	Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
KM3/BTZ	IC₅₀	2040 nM Compound: MS-275	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
KM3/BTZ	IC₅₀	98 nM Compound: MS-275	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay	[PMID: 32267687]
LN-18	GI₅₀	0.917 μM Compound: Entinostat	Antiproliferative activity against human LN-18 cells incubated for 3 days by alamar blue assay Antiproliferative activity against human LN-18 cells incubated for 3 days by alamar blue assay	[PMID: 38340642]
LNCaP	IC₅₀	0.36 μM Compound: 4, MS-275	Antiproliferative activity against human LNCap by MTT assay Antiproliferative activity against human LNCap by MTT assay	[PMID: 18166465]
MCF7	IC₅₀	5 μM Compound: 4 (MS-275)	Inhibitory concentration against breast MCF-7 cell line Inhibitory concentration against breast MCF-7 cell line	[PMID: 12593661]
MCF7	IC₅₀	4.3 μM Compound: 1g, MS-275	Inhibition of human MCF7 cells Inhibition of human MCF7 cells	[PMID: 18247554]
MCF7	IC₅₀	7.881 μM Compound: MS-275	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26140961]
MCF7	IC₅₀	0.35 μM Compound: 10; MS-275	Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay	[PMID: 26613635]
MCF7	IC₅₀	4.02 μM Compound: Entinostat	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28340413]
MCF7	GI₅₀	19.26 μM Compound: MS-275	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28629630]
MCF7	IC₅₀	6.96 μM Compound: MS-275	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 39031090]
MDA-MB-231	IC₅₀	3 μM Compound: 4 (MS-275)	Inhibitory concentration against breast MDA-MB-231 cell line Inhibitory concentration against breast MDA-MB-231 cell line	[PMID: 12593661]
MDA-MB-231	IC₅₀	4.63 μM Compound: MS-275	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
MDA-MB-231	GI₅₀	1.41 μM Compound: 6; MS-275	Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
MDA-MB-231	IC₅₀	2.55 μM Compound: MS-275	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 29787262]
MDA-MB-231	IC₅₀	2.6 μM Compound: 5; MS-275	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32325365]
MDA-MB-231	IC₅₀	2.63 μM Compound: 5; MS-275	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
MDA-MB-231	IC₅₀	1 μM Compound: 69	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by ALDEFLUOR assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by ALDEFLUOR assay	[PMID: 33650861]
MDA-MB-231	IC₅₀	4.63 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
MDA-MB-468	IC₅₀	2.73 μM Compound: 5; MS-275	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
MGC-803	IC₅₀	4.89 μM Compound: MS275	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
MGC-803	IC₅₀	58.55 μM Compound: MS-275	Cytotoxicity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
MKN-45	IC₅₀	4.16 μM Compound: MS-275 (4)	Compound was tested for antiproliferative activity against human MKN45 cancer cell lines Compound was tested for antiproliferative activity against human MKN45 cancer cell lines	[PMID: 14667227]
MKN-45	IC₅₀	4.16 μM Compound: 1g, MS-275	Antiproliferative activity against human MKN45 cells Antiproliferative activity against human MKN45 cells	[PMID: 18247554]
MKN-45	IC₅₀	1200 nM Compound: 6; MS-275	Growth inhibition of human MKN45 cells after 48 hrs by SRB assay Growth inhibition of human MKN45 cells after 48 hrs by SRB assay	[PMID: 30476825]
MOLT-4	IC₅₀	0.65 μM Compound: MS-275	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 28511906]
MOLT-4	IC₅₀	0.45 μM Compound: MS-275	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 29787262]
MV4-11	EC₅₀	<30 nM Compound: entinostat	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay	[PMID: 27754681]
MV4-11	EC₅₀	806.2 nM Compound: Ent; MS275	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis	[PMID: 32321249]
MV4-11	IC₅₀	0.24 μM Compound: 11; MS-275	Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 33077265]
MV4-11	IC₅₀	0.71 μM Compound: MS275	Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter-blue viability assay Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter-blue viability assay	[PMID: 38060537]
MV4-11	IC₅₀	0.24 μM Compound: MS-275	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	[PMID: 38964169]
NCI-H1299	IC₅₀	>4000 nM Compound: 6, SNDX-275	Antiproliferative activity against human H1299 cells Antiproliferative activity against human H1299 cells	[PMID: 21650221]
NCI-H1299	IC₅₀	6.74 μM Compound: MS275	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
NCI-H1299	IC₅₀	>2 μM Compound: 5; MS-275	Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
NCI-H446	IC₅₀	1 μM Compound: 4 (MS-275)	Inhibitory concentration against lung H446 cell line Inhibitory concentration against lung H446 cell line	[PMID: 12593661]
NCI-H661	IC₅₀	2.19 μM Compound: MS-275	Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
NCI-H661	IC₅₀	2.19 μM Compound: Entinostat	Antiproliferative activity against human NCI-H661 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H661 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
NCI-H661	IC₅₀	>2 μM Compound: 5; MS-275	Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
NIH3T3	IC₅₀	2.42 μM Compound: MS275	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 31003060]
PC-3	IC₅₀	59.06 μM Compound: MS-275	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 18701301]
PC-3	IC₅₀	6.36 μM Compound: Entinostat	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28340413]
PC-3	GI₅₀	0.43 μM Compound: 6; MS-275	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
PC-3	IC₅₀	4.89 μM Compound: MS-275	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28511906]
PC-3	GI₅₀	19.09 μM Compound: MS-275	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28629630]
PC-3	IC₅₀	>5 μM Compound: MS-275	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29787262]
PC-3	GI₅₀	0.087 μM Compound: Entinostat	Antiproliferative activity against human PC-3 cells incubated for 3 days by alamar blue assay Antiproliferative activity against human PC-3 cells incubated for 3 days by alamar blue assay	[PMID: 38340642]
PrEC	GI₅₀	2.23 μM Compound: Entinostat	Cytotoxicity against human PrEC cells incubated for 3 days by alamar blue assay Cytotoxicity against human PrEC cells incubated for 3 days by alamar blue assay	[PMID: 38340642]
RS4-11	IC₅₀	0.3 μM Compound: MS275	Cytotoxicity against human RS4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter-blue viability assay Cytotoxicity against human RS4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter-blue viability assay	[PMID: 38060537]
S2	IC₅₀	940 nM Compound: 6, MS-275	Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells	[PMID: 19317450]
Sf9	IC₅₀	>10 μM Compound: Entinostat	Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells ZMAL as substrate incubated for 90 mins by fluorescence assay Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells ZMAL as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	0.505 μM Compound: Entinostat	Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	0.519 μM Compound: Entinostat	Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate incubated for 90 mins by fluorescence assay Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	2.85 μM Compound: Entinostat	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 9 Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 9	[PMID: 31762274]
Sf9	IC₅₀	>1 μM Compound: MS-275	Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	>1 μM Compound: MS-275	Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	>1 μM Compound: MS-275	Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	>1 μM Compound: MS-275	Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	>1 μM Compound: MS-275	Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.118 μM Compound: MS-275	Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.247 μM Compound: MS-275	Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	>10000 nM Compound: Ent; MS275	Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs b Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs b	[PMID: 32321249]
Sf9	IC₅₀	>10000 nM Compound: Ent; MS275	Inhibition of recombinant human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by Inhibition of recombinant human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by	[PMID: 32321249]
Sf9	IC₅₀	77.18 nM Compound: Ent; MS275	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr fo Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr fo	[PMID: 32321249]
Sf9	IC₅₀	>10000 nM Compound: Ent; MS275	Inhibition of recombinant full length human C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluoresce Inhibition of recombinant full length human C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluoresce	[PMID: 32321249]
Sf9	IC₅₀	9.32 μM Compound: 2; MS-275	Inhibition of full length N-terminal GST-tagged human recombinant HDAC6 (1 to 1215 residues) expressed in Baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys (Ac)-AMC as substrate pretreated for 5 mins followed by substrate addition and measured after 30 Inhibition of full length N-terminal GST-tagged human recombinant HDAC6 (1 to 1215 residues) expressed in Baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys (Ac)-AMC as substrate pretreated for 5 mins followed by substrate addition and measured after 30	[PMID: 34097389]
SGC-7901	IC₅₀	>200 μM Compound: MS-275	Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
SGC-7901	IC₅₀	0.98 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
SK-BR-3	IC₅₀	0.87 μM Compound: MS-275 (4)	Compound was tested for antiproliferative activity against human SK-BR-3 cancer cell lines Compound was tested for antiproliferative activity against human SK-BR-3 cancer cell lines	[PMID: 14667227]
SK-BR-3	IC₅₀	0.87 μM Compound: 1g, MS-275	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 18247554]
SKM-1	IC₅₀	389 nM Compound: MS-275	Cytotoxicity against human SKM-1 cells assessed as viable cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human SKM-1 cells assessed as viable cells incubated for 72 hrs by CCK8 assay	[PMID: 37184921]
SMMC-7721	IC₅₀	5.97 μM Compound: MS275	Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
SMMC-7721	IC₅₀	5.97 μM Compound: MS275	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
SNU-16	IC₅₀	2194.59 nM Compound: MS-275 (4)	Inhibitory activity against Histone deacetylase (HDAC) from SNU-16 (human gastric adenocarcinoma) cells Inhibitory activity against Histone deacetylase (HDAC) from SNU-16 (human gastric adenocarcinoma) cells	[PMID: 14667227]
SNU-16	IC₅₀	233 nM Compound: 1g, MS-275	Inhibition of HDAC from human SNU16 cells Inhibition of HDAC from human SNU16 cells	[PMID: 18247554]
SW48	IC₅₀	5 μM Compound: 4 (MS-275)	Inhibitory concentration against colon SW48 cell line Inhibitory concentration against colon SW48 cell line	[PMID: 12593661]
SW-620	IC₅₀	3.2 μM Compound: 1g, MS-275	Inhibition of human SW620 cells Inhibition of human SW620 cells	[PMID: 18247554]
T-24	IC₅₀	2.5 μM Compound: 4 (MS-275)	Inhibitory concentration against bladder T24 cell line Inhibitory concentration against bladder T24 cell line	[PMID: 12593661]
THP-1	IC₅₀	2.3 μM Compound: MS-275	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
U-251	GI₅₀	6.5 μM Compound: MS-275, SNDX-275	Growth inhibition of human U251 cells after 2 days by MTT assay Growth inhibition of human U251 cells after 2 days by MTT assay	[PMID: 22541394]
U-251	IC₅₀	>30 μM Compound: MS-275	Antiproliferative activity against human U-251 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human U-251 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34656900]
U-266	IC₅₀	6.1 μM Compound: MS275	Antiproliferative activity against human U266 cells after 48 hrs by MTT assay Antiproliferative activity against human U266 cells after 48 hrs by MTT assay	[PMID: 28415009]
U-87MG ATCC	IC₅₀	4.34 μM Compound: MS-275	Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34656900]
U-937	IC₅₀	0.3 μM Compound: MS-275	Inhibition of human HDAC1 in U937 cells by immunoprecipitation assay Inhibition of human HDAC1 in U937 cells by immunoprecipitation assay	[PMID: 18381238]
U-937	IC₅₀	142 μM Compound: MS-275	Inhibition of human HDAC4 in U937 cells by immunoprecipitation assay Inhibition of human HDAC4 in U937 cells by immunoprecipitation assay	[PMID: 18381238]
U-937	IC₅₀	0.55 μM Compound: MS-275	Antiproliferative activity against human U937 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human U937 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
U-937	IC₅₀	0.55 μM Compound: Entinostat	Antiproliferative activity against human U937 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human U937 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
U-937	IC₅₀	0.77 μM Compound: MS275	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 28415009]
WI-38	IC₅₀	>20 μM Compound: MS-275	Toxicity in human WI38 cells Toxicity in human WI38 cells	[PMID: 18212103]

In Vitro

Binding affinity of Entinostat (MS-275) against HDAC1 and HDAC2 is 282 nM and 156 nM, respectively^[1]. Effects of the HDAC inhibitor Entinostat (MS-275) have been examined in human leukemia and lymphoma cells (U937, HL-60, K562, and Jurkat) as well as in primary acute myelogenous leukemia blasts in relation to differentiation and apoptosis. MS-275 displays dose-dependent effects in each of the cell lines. When administered at a low concentration (e.g., 1 μM), MS-275 exhibits potent antiproliferative activity, inducing p21CIP1/WAF1-mediated growth arrest and expression of differentiation markers (CD11b) in U937 cells. Entinostat (MS-275) potently induces cell death, triggering apoptosis in ~70% of cells at 48 h^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Entinostat (MS-27-275) at 49 mg/kg shows marked antitumor effects against KB-3-1, 4-1St, and St-4 tumor lines, and a moderate effect against Capan-1 tumor. Entinostat at 24.5 mg/kg and 12.3 mg/kg also shows significant effects against these tumors. In addition, oral administration of Entinostat apparently increases the level of histone acetylation in HT-29 tumor xenografts 4-24 h after the administration^[3]. MS-275 administration (3.5 mg/kg i.p.) to Experimental autoimmune neuritis (EAN) rats once daily from the appearance of first neurological signs greatly reduces the severity and duration of EAN and attenuated local accumulation of macrophages, T cells and B cells, anddemyelination of sciatic nerves. In addition, MS-275 treatment increases proportion of infiltrated Foxp3⁺ cells and anti-inflammatory M2 macrophages in sciatic nerves of EAN rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 209783-80-2
Appearance Solid
Molecular Weight 376.41
Formula C₂₁H₂₀N₄O₃
Color White to light yellow
SMILES

O=C(NCC1=CC=C(C=C1)C(NC2=CC=CC=C2N)=O)OCC3=CC=CN=C3
Synonyms

MS-275; SNDX-275
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (91)

All RT-PCRWBFlow CytometryApoptosis AnalysisCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cell

Acetylation Blocks cGAS Activity and Inhibits Self-DNA-Induced Autoimmunity. [Abstract]

2019 Mar 7;176(6):1447-1460.e14. PMID: 30799039

Entinostat purchased from MedChemExpress. Usage Cited in: Cell. 2019 Mar 7;176(6):1447-1460.e14. [Abstract]

Trex1−/− mice (n = 6) were given daily administration (i.p.) of MS-275 (20 mg/kg) or DMSO for 10 days, mRNA levels of ISGs in mouse hearts were analyzed by qPCR.
Cell Metab

Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]

2022 Mar 1;34(3):424-440.e7. PMID: 35150639
Mol Cell

CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. [Abstract]

2023 Dec 7;83(23):4370-4385.e9. PMID: 38016475
Nat Commun

IDH2 lactylation promotes angiogenesis in murine diabetic myocardial infarction via blocking Cav1-eNOS interaction. [Abstract]

2025 Dec 19. PMID: 41419771

Entinostat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 19. [Abstract]

Western blot analysis of the expression levels of HDAC1 and IDH2-K272la 311 in CMECs treated with the HDAC1inhibitor Entinostat (250 nM; 24 h) under NOD and HOD 312 stimulation (n = 6).
Nat Commun

Small molecule in situ resin capture provides a compound first approach to natural product discovery. [Abstract]

2024 Jun 19;15(1):5230. PMID: 38898025
Nat Commun

Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML. [Abstract]

2024 Jun 4;15(1):4739. PMID: 38834613

Entinostat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 4;15(1):4739. [Abstract]

Annexin V/propidium iodide (PI) staining after 72 hr of entinostat (4 μM) treatment.

Entinostat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 4;15(1):4739. [Abstract]

Apoptotic fold increase, expressed as a percentage of annexin V-positive cells relative to vehicle control with entinostat (1-4 μM; 72 h) treatment.
Adv Sci (Weinh)

GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion. [Abstract]

2026 Mar 2:e16411. PMID: 41772945
Leukemia

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. [Abstract]

2023 Jun;37(6):1336-1348. PMID: 36977823

Entinostat purchased from MedChemExpress. Usage Cited in: Leukemia. 2023 Jun;37(6):1336-1348. [Abstract]

Percent apoptotic cells following KO of mtNPM1 and treatment with entinostat (0-1000 nM) at the indicated concentrations for 48 hours.
J Nanobiotechnology

Biosynthesized nanoparticles of Tibetan medicine mercuric sulfide preparation to promote endocytosis and realize drug crossing through blood brain barrier. [Abstract]

2025 Jun 16;23(1):445. PMID: 40524151
Sci Adv

Atf3-mediated metabolic reprogramming in hepatic macrophage orchestrates metabolic dysfunction-associated steatohepatitis. [Abstract]

2024 Jul 26;10(30):eado3141. PMID: 39047111
EBioMedicine

Ketogenesis acts as an endogenous protective programme to restrain inflammatory macrophage activation during acute pancreatitis. [Abstract]

2022 Apr;78:103959. PMID: 35339899
Clin Cancer Res

Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair. [Abstract]

2023 Nov 14;29(22):4644-4659. PMID: 37725585
Clin Cancer Res

Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. [Abstract]

2020 Apr 15;26(8):2011-2021. PMID: 31937620
Cancer Lett

HOX code-based stratification reveals RUNX1T1-HDAC reprogramming as a targetable driver of lineage plasticity across cancers. [Abstract]

2026 Mar 28:218465. PMID: 41912135
Cancer Lett

Forkhead box protein FOXK1 disrupts the circadian rhythm to promote breast tumorigenesis in response to insulin resistance. [Abstract]

2024 Jul 31:217147. PMID: 39094826
Cancer Lett

HDAC4 mediated LHPP deacetylation enhances its destabilization and promotes the proliferation and metastasis of nasopharyngeal carcinoma. [Abstract]

2023 May 28:562:216158. PMID: 37023940
Int J Biol Sci

2021; 17(10):2380-2398.
Cell Death Dis

Deacetylation of TALDO1 by HDAC6 promotes glycolysis and nasopharyngeal carcinoma progression through a moonlighting function. [Abstract]

2025 Oct 21;16(1):743. PMID: 41120289
Cell Death Dis

HAT1/HDAC2 mediated ACSL4 acetylation confers radiosensitivity by inducing ferroptosis in nasopharyngeal carcinoma. [Abstract]

2025 Mar 6;16(1):160. PMID: 40050614
Cell Death Dis

IL-4 inhibits regulatory T cells differentiation by HDAC9-mediated epigenetic regulation. [Abstract]

2021 May 18;12(6):501. PMID: 34006836
Proc Natl Acad Sci U S A

IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer. [Abstract]

2022 Aug 2;119(31):e2201376119. PMID: 35878022
Proc Natl Acad Sci U S A

MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. [Abstract]

2019 Feb 19;116(8):2961-2966. PMID: 30718431
Cell Commun Signal

Unveiling the signal valve specifically tuning the TGF-β1 suppression of osteogenesis: mediation through a SMAD1-SMAD2 complex. [Abstract]

2025 Jan 22;23(1):38. PMID: 39844165
Int J Biol Macromol

Nucleolar and spindle-associated protein 1 (NUSAP1) promotes thyroid cancer dedifferentiation via BCAT1-mediated metabolic-epigenetic crosstalk. [Abstract]

2026 Jul:371:153021. PMID: 42276487
Int J Biol Macromol

Histone acetylation activated-IGF2BP3 regulates cyclin D1 mRNA stability to drive cell cycle transition and tumor progression of hepatocellular carcinoma. [Abstract]

2025 May;306(Pt 3):141678. PMID: 40037458
Acta Pharmacol Sin

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. [Abstract]

2022 Feb;43(2):457-469. PMID: 33850273
Neoplasia

Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat. [Abstract]

2025 Jan 25:60:101121. PMID: 39864337
Br J Pharmacol

Microglial forkhead box O3a deficiency attenuates LPS-induced neuro-inflammation and depressive-like behaviour through regulating the expression of peroxisome proliferator-activated receptor-γ. [Abstract]

2024 Oct;181(20):3908-3925. PMID: 38881194
Knowl Based Syst

2026 Mar 5.
Biomed Pharmacother

Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer. [Abstract]

2024 May 16:175:116743. PMID: 38759290
Oncogene

HDAC1/2-mediated deacetylation of KLF9 promotes the malignant progression of nasopharyngeal carcinoma via CDH17. [Abstract]

2025 Sep;44(35):3183-3198. PMID: 40615689
Oncogene

RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-κB activation and ovarian cancer progression. [Abstract]

2024 Feb;43(6):420-433. PMID: 38092960
Oncogene

BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. [Abstract]

2021 Apr;40(15):2711-2724. PMID: 33712705
PLoS Biol

The Rpd3 histone deacetylase is a critical regulator of temperature-mediated morphogenesis and virulence in the human fungal pathogen Histoplasma. [Abstract]

2026 Mar 17;24(3):e3003341. PMID: 41843621
Aging Cell

Age-Dependent Regulation of Hippocampal Inflammation by the Mitochondrial Translocator Protein in Mice. [Abstract]

2025 Jun;24(6):e70039. PMID: 40275629
Neurotherapeutics

Transcriptionally distinct malignant neuroblastoma populations show selective response to adavosertib treatment. [Abstract]

2025 Apr;22(3):e00575. PMID: 40118716
J Med Chem

Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy. [Abstract]

2025 Feb 20. PMID: 39979078
J Med Chem

Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. [Abstract]

2024 Sep 12;67(17):15098-15117. PMID: 39145486
Mol Ther Nucleic Acids

2025 Dec 15.
JCI Insight

Transcriptional control of a collagen deposition and adhesion process that promotes lung adenocarcinoma growth and metastasis. [Abstract]

2022 Jan 11;7(1):e153948. PMID: 34874914
Biochem Pharmacol

HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer. [Abstract]

2024 Jul:225:116257. PMID: 38705532
Biochem Pharmacol

A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo. [Abstract]

2022 Jul:201:115070. PMID: 35526597
J Ethnopharmacol

The activation of histone deacetylases 4 prevented endothelial dysfunction: A crucial mechanism of HuangqiGuizhiWuwu Decoction in improving microcirculation dysfunction in diabetes. [Abstract]

2023 May 10:307:116240. PMID: 36764560
Cells

HDAC Inhibition Induces Transient Phenotypic Inertia in Dormant OCCC Spheroids by Derepression of Cell Cycle Genes. [Abstract]

2026 Apr 10;15(8):673. PMID: 42041541
Commun Biol

CBX4 enhances acute monocytic leukemia development via HDAC-mediated suppression of Runx1. [Abstract]

2026 Jun 1. PMID: 42225948
Commun Biol

Therapeutic targeting SPI1 in combination with erastin promotes ferroptosis in ccRCC. [Abstract]

2025 Dec 10;8(1):1772. PMID: 41372608
Drug Des Devel Ther

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation. [Abstract]

2024 Sep 12:18:4065-4088. PMID: 39286286
Drug Des Devel Ther

Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). [Abstract]

2018 Apr 30:12:1009-1017. PMID: 29750014
Inflammation

Narciclasine Alleviates Endothelial Inflammation and Atherosclerosis Initiation by Inhibiting Histone Lactylation-Mediated NF-κB Activation. [Abstract]

2026 Jan 16;49(1):49. PMID: 41543766
Int J Mol Sci

In Vivo Two-Photon Imaging Analysis of Dynamic Degradation of Hepatic Lipid Droplets in MS-275-Treated Mouse Liver. [Abstract]

2022 Sep 1;23(17):9978. PMID: 36077368
Front Pharmacol

A Class I Histone Deacetylase Inhibitor Attenuates Insulin Resistance and Inflammation in Palmitate-Treated C2C12 Myotubes and Muscle of HF/HFr Diet Mice. [Abstract]

2020 Dec 10:11:601448. PMID: 33362555
Mol Cancer Res

Epigenetic Silencing of BMP6 by the SIN3A-HDAC1/2 Repressor Complex Drives Melanoma Metastasis via FAM83G/PAWS1. [Abstract]

2022 Feb;20(2):217-230. PMID: 34610961
Antibiotics (Basel)

High-Throughput Identification of Epigenetic Compounds to Enhance Chicken Host Defense Peptide Gene Expression. [Abstract]

2022 Jul 12;11(7):933. PMID: 35884187
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Cancers (Basel)

c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation. [Abstract]

2022 Jan 18;14(3):457. PMID: 35158730
FASEB J

MS275 Inhibits Neuroblastoma Cell Growth by Mediating H3K27ac/PROX1 Axis In Silico and In Vitro. [Abstract]

2025 Jul 15;39(13):e70797. PMID: 40601211
J Dermatol Sci

Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response. [Abstract]

2023 Jun;110(3):89-98. PMID: 37173222
J Cell Physiol

Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway. [Abstract]

2019 Dec;234(12):22400-22410. PMID: 31120582
Sci Rep

Disruption of zinc homeostasis reduces histone acetylation levels in normal and tumor cells. [Abstract]

2026 Jan 10;16(1):4983. PMID: 41519875
Exp Cell Res

Inhibition of 14-3-3ε by K50 acetylation activates YAP1 to promote cholangiocarcinoma growth. [Abstract]

2022 Dec 15;421(2):113404. PMID: 36341908
Exp Cell Res

Diacylglycerol kinase γ predicts prognosis and functions as a tumor suppressor by negatively regulating glucose transporter 1 in hepatocellular carcinoma. [Abstract]

2018 Dec 15;373(1-2):211-220. PMID: 30399372
Int J Parasitol Drugs Drug Resist

2026 May 17;31:100649.
Toxicol Appl Pharmacol

MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells. [Abstract]

2020 May 15:395:114971. PMID: 32217144
FEBS Lett

Platycodin D reduces PD-L1 levels by inhibiting LXR-β activity and combines with nintedanib to enhance the tumor-killing effect of T cells. [Abstract]

2024 Dec;598(24):3053-3070. PMID: 39428320
Carcinogenesis

Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. [Abstract]

2015 Feb;36(2):192-201. PMID: 25477340

Entinostat purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2015 Feb;36(2):192-201. [Abstract]

Entinostat shows a mild inhibitory effect on cell growth.
Neuroscience

Treatment with Non-specific HDAC Inhibitors Administered after Disease Onset does not Delay Evolution in a Mouse Model of Progressive Multiple Sclerosis. [Abstract]

2021 Jun 15:465:38-45. PMID: 33862148
PLoS One

Polypyrimidine tract binding proteins PTBP1 and PTBP2 associate with distinct proteins and have distinct post-translational modifications in neuronal nuclear extract. [Abstract]

2025 Jun 4;20(6):e0325143. PMID: 40465779
PLoS One

Entinostat reverses P-glycoprotein activation in snail-overexpressing adenocarcinoma HCC827 cells. [Abstract]

2018 Jul 6;13(7):e0200015. PMID: 29979729

Entinostat purchased from MedChemExpress. Usage Cited in: PLoS One. 2018 Jul 6;13(7):e0200015. [Abstract]

Western blot analysis of AcH3 and H3 in HCC827 whole cell lysate. Cells are treated with Entinostat (Ent) for 4 days in vitro. Band densities are determined with a Luminescent Image Analyzer LAS-3000, and AcH3 densities are normalized by H3.
PLoS One

Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites. [Abstract]

2017 Jun 13;12(6):e0178203. PMID: 28609444
Chronobiol Int

Induction of Dbp by a histone deacetylase inhibitor is involved in amelioration of insulin sensitivity via adipocyte differentiation in ob/ob mice. [Abstract]

2019 Jul;36(7):955-968. PMID: 31070057
bioRxiv

2026 Feb 10.
SSRN

2025 Nov 16.
bioRxiv

2025 Oct 3.
bioRxiv

HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-Driven Small Cell Lung Cancer. [Abstract]

2025 Aug 9:2025.08.06.668958. PMID: 40970137
bioRxiv

2025 Aug 04.
Dartmouth College

2025.
University of Califomia San Francisco

2025.
bioRxiv

Short chain fatty acids regulate the chromatin landscape and distinct gene expression changes in human colorectal cancer cells. [Abstract]

2025 May 13:2025.05.07.652677. PMID: 40463142
Hong Kong Polytechnic University

2025.
bioRxiv

A nuclear branched-chain amino acid catabolism pathway controls histone propionylation in pancreatic cancer. [Abstract]

2025 Apr 26:2025.04.23.650241. PMID: 40568091
bioRxiv

2025 March 17.
bioRxiv

2025 March 12.
bioRxiv

2025 January 15.
bioRxiv

The CoREST-complex regulates MYC stability and promotes post-transcriptional mRNA splicing in melanoma. [Abstract]

2024 Dec 23:2024.12.23.630174. PMID: 39764010
Patent

US20240252638A1.
bioRxiv

The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors. [Abstract]

2024 Aug 19:2024.08.17.607802. PMID: 39229179
Research Square Preprint

2024 Jan 2.
Research Square Print

2023 Mar 9.
Research Square Preprint

2021 Dec.
Albert-ludwigs-university Of Freiburg

2019 Dec.
Journal Of Zhengzhou University

2018 (05): 547-552.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (132.83 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6567 mL

13.2834 mL

26.5668 mL

5 mM

0.5313 mL

2.6567 mL

5.3134 mL

10 mM

0.2657 mL

1.3283 mL

2.6567 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Kinase Assay^[1]

Biochemical assays of HDAC activity are carried out by Nanosyn in a reaction volume of 10 μL in 384-well microplates. A standard enzymatic reaction contains 5 μL of 2× HDAC inhibitor (e.g., Entinostat), 4 μL of 2.5× enzyme, and 1 μL of 10× substrate in assay buffer (100 mM HEPES, pH 7.5, 25 mM KCl, 0.1% BSA, 0.01% Triton X-100, 1% DMSO). Final concentration of all HDACs in the enzymatic assays is between 0.5 and 5 nM. A final substrate concentration of 1 μM FAM-RHKK(Ac)-NH₂ or FAM-RHKK(trifluoroacetyl)-NH₂ is used in all assays and found to be below the determined K_m,app for each enzyme^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

SH-SY5Y cells are maintained under normal culture conditions in a humidified incubator at 37°C with 5% CO₂ and are split twice weekly. Cells are plated in black 384-well plates at 2500 cells/well in 20-μL volume of DMEM/F-12 culture media supplemented with 10% FBS and permitted to adhere overnight. The following day, HDAC inhibitors (e.g., Entinostat) are serially diluted in 100% DMSO, and this series is subsequently cross-diluted into culture media. 5 μL of compound (e.g., Entinostat) diluted in media is added to the appropriate well of the cell plate to afford the indicated final concentration of inhibitor (e.g., Entinostat) with a final 0.1% DMSO. Treated cells are incubated under normal tissue culture conditions for 6, 24, 48, 72, or 96 h prior to quantitation of cellular ATP levels as measured using CellTiter-Glo reagents. Similarly, after 6 h of incubation with HDAC inhibitors (e.g., Entinostat), media from separate cell plates are aspirated, and cells are washed once with media containing no inhibitors. 25 μL of media supplemented with 10% FBS and 0.1% DMSO (no inhibitors) is added back to the cells, and cellular ATP levels are determined using CellTiter-Glo after 24, 48, 72, or 96 h of incubation. Luminescence is measured at each time point using an Envision Instrument with a 0.1 s count time^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]^[4]

Mice^[3]
A2780 cells (9×10⁶) are suspended in PBS and are injected subcutaneously into the flank of nude mouse. For the other tumor lines, KB-3-1, HCT-15, 4-1St, Calu-3, St-4, Capan-1, and HT-29, tumors are passaged several times before starting in vivo antitumor testing, and a tumor lump (2-3 mm in diameter) is transplanted subcutaneously into the flank of a nude mouse by using a trocar needle. Treatment (four or five mice in each experimental group) with the drugs is started after the tumors are confirmed to have grown in the body (tumor size, 20-100 mm³). Entinostat is administered orally once daily 5 days per week for 4 weeks. Tumor length and width are monitored twice weekly, and tumor volume is calculated.
Rats^[4]
Male Lewis rats (8-10 weeks, 170-200 g) are housed under a 12-h light/dark cycle with free access to food and water. For therapeutic treatment, EAN rats receive i.p. injection of MS-275 (3.5 mg/kg) daily from day 10 to day 14 (six rats/group). For injection, MS-275 is suspended in phosphate buffered saline (PBS) and the same volume (1 mL) of PBS is given to control rats.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lauffer BE, et al. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem. 2013 Sep 13;288(37):26926-43. [Content Brief]

[2]. Rosato RR, et al. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003 Jul 1;63(13):36 [Content Brief]

[3]. Saito A, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A, 1999, 96(8), 4592-4597. [Content Brief]

[4]. Zhang ZY, et al. MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neurosci, 2010, 169, 370-377. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6567 mL	13.2834 mL	26.5668 mL	66.4169 mL
	5 mM	0.5313 mL	2.6567 mL	5.3134 mL	13.2834 mL
	10 mM	0.2657 mL	1.3283 mL	2.6567 mL	6.6417 mL
	15 mM	0.1771 mL	0.8856 mL	1.7711 mL	4.4278 mL
	20 mM	0.1328 mL	0.6642 mL	1.3283 mL	3.3208 mL
	25 mM	0.1063 mL	0.5313 mL	1.0627 mL	2.6567 mL
	30 mM	0.0886 mL	0.4428 mL	0.8856 mL	2.2139 mL
	40 mM	0.0664 mL	0.3321 mL	0.6642 mL	1.6604 mL
	50 mM	0.0531 mL	0.2657 mL	0.5313 mL	1.3283 mL
	60 mM	0.0443 mL	0.2214 mL	0.4428 mL	1.1069 mL
	80 mM	0.0332 mL	0.1660 mL	0.3321 mL	0.8302 mL
	100 mM	0.0266 mL	0.1328 mL	0.2657 mL	0.6642 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Entinostat

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Entinostat

All HDAC Isoforms

Biological Activity

Chemical Information

Publications (91)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Entinostat

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Entinostat

All HDAC Isoforms

Biological Activity

Chemical Information

Publications (91)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Entinostat Related Classifications

HY-12163 Related Classifications